New Delhi, July 21: India has approved its first vaccine for the prevention of dengue, marking a significant development in the country’s efforts to strengthen protection against one of its fastest-growing mosquito-borne diseases. The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Qdenga, a live, attenuated tetravalent dengue vaccine developed by Takeda GmbH, Germany.
According to an official statement, the vaccine will be imported into the country by Takeda Biopharmaceuticals India Pvt. Ltd. The approval followed a scientific evaluation of the vaccine’s quality, safety and efficacy under the provisions of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945.
Qdenga is a live, attenuated tetravalent vaccine developed using recombinant DNA technology. It is designed to provide protection against all four dengue virus serotypes responsible for causing the disease. The vaccine is supplied as a freeze-dried powder for reconstitution and is administered through a subcutaneous injection.

The vaccine has been approved for individuals between the ages of four and 60 years. The recommended immunisation schedule consists of two doses of 0.5 ml each, administered three months apart.
The Health Ministry stated that the approval is supported by data generated through an extensive global clinical development programme evaluating the vaccine’s safety, immunogenicity and efficacy in both dengue-endemic and non-endemic countries.
Clinical trials included participants from more than eight countries, including Brazil, Thailand and Sri Lanka. The regulatory assessment also considered findings from a pivotal Phase III clinical study conducted in India involving participants aged four to 60 years.
According to the Ministry, Qdenga has already secured regulatory approval in 42 countries, including the European Union, the United Kingdom, Switzerland, Indonesia, Malaysia and Thailand. The vaccine has also received prequalification from the World Health Organization.
Officials said more than 24 million doses have already been distributed globally. The Ministry further stated that post-marketing surveillance has demonstrated a favourable safety profile, with no significant safety concerns reported.

The government said the vaccine is expected to complement existing dengue prevention measures under the National Vector Borne Disease Control Programme, including vector control, disease surveillance, early diagnosis and case management.
The Ministry, however, emphasised that vaccination is intended to strengthen ongoing dengue prevention efforts and not replace them. It reiterated the importance of eliminating mosquito breeding sites and following personal protective measures to reduce the spread of dengue.
The government said the approval reflects its commitment to ensuring timely access to safe, effective and quality-assured vaccines through a science-based regulatory framework.


